 |
|
|
| |
In Null Responders 4 Week Peg/Rbv Lead-In Predicts SVR' - Different Likelihood of Achieving SVR on a Telaprevir-containing Regimen Among Null Responders, Partial Responders and Relapsers Irrespective of Similar Responses after a Peginterferon/Ribavirin 4-week Lead-in Phase: REALIZE Study Subanalysis
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-9 2011 SF
Stefan Zeuzem,1 Graham R Foster,2 Pietro Andreone,3 Stanislas Pol,4 Eric J Lawitz,5 Moises Diago,6 Stuart Roberts,7 Paul J Pockros,8 Zobair Younossi,9 Isabelle Lonjon-Domanec,10 Rudolf Van Heeswijk,11 Sandra De Meyer,11 Donghan Luo,12 Shelley George,13 James Witek,12 Gaston Picchio12
1Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 2Queen Marys University of London, Institute of Cell and Molecular Science, London, UK; 3Universita di Bologna, Bologna, Italy; 4Université Paris Descartes, INSERM Unite 1016, and Assistance Publique-Hopitaux de Paris, Cochin Hospital, Paris, France; 5Alamo Medical Research, San Antonio, TX, USA; 6Hospital General de Valencia, Valencia, Spain; 7Department of Gastroenterology, Alfred Hospital, Melbourne, VIC, Australia; 8Scripps Clinic and The Scripps Research Institute, La Jolla, CA, USA; 9Center for Liver Diseases and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; 10Janssen Pharmaceuticals, Paris, France; 11Tibotec BVBA, Beerse, Belgium; 12Tibotec Inc., Titusville, NJ, USA; 13Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA
|
| |
|
|
|
|
|
